Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-01

Study Completion Date

2022-10-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigational lotion is envisaged as an short- and long term "Ease \& Prevent" monotherapy for adults and children with mild to moderate eczema. With itch representing the most burdensome symptom in eczema, the main objectives with the lotion is fast and efficient itch relief, high tolerability, and high short- and long term safety. This phase 1 study aims to monitor skin tolerability, and how much of the active compound that is absorbed to the bloodstream.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit

NCT00637611

Seasonal Allergic Rhinitis

COMPLETED PHASE4

A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)

NCT01469234

Rhinitis

COMPLETED PHASE4

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

NCT00044811

Asthma

COMPLETED PHASE3

A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis

NCT05692154

Seasonal Allergic Rhinitis

COMPLETED PHASE3

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

NCT00044824

Asthma

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Fexofenadine Hydrochloride Topical Lotion 1% (OP2101) is a novel formulation developed for the treatment of skin disorders characterized by pruritus. Research show that oral Fexofenadine Hydrochloride (FX) may lead to a small improvement of pruritus in patients with Atopic Dermatitis (AD). In clinical practice, oral antihistamines are widely used off-label for pruritus relief in AD, indicating a discrepancy in trial outcomes and real-life experience. The pre-study thesis postulates that the antipruritic effect of FX can be leveraged in a dose-response relationship facilitated by high topical concentration of FX in direct contact with the pathological process of the skin. The sponsor also suggest that the Cytosolic phospholipase A2 (cPLA2) blocking property of FX is an untapped resource that is likely to be dose-response dependent and manifested by means of high topical concentration in proximity to the inflammatory process. The repositioning of FX to a topical treatment has the potential for high safety, efficacy, fast relief, and ease of use. OP2101 is also aimed at inflammation control, suppression of bacterial imbalance, moisture retention, upregulation of antimicrobial peptides, and skin barrier restoration. As such, it targets six of the pathological pillars of AD. Assessment of topical tolerability and skin adsorption (systemic exposure) are the main objectives in this phase 1 study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atopic Dermatitis Atopic Dermatitis Eczema Atopic Rash Rash Pruritus Urticaria Urticaria Chronic Psoriasis Psoriasis Vulgaris Skin Rash Skin Inflammation Eczema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

The study is an 'Open Label, Single-Dose, Single-Treatment, Single-Period Safety and Bioavailability Study in Healthy, Adult, Male Human Subjects, where the subjects will be housed in the clinical facility from not less than 11 hours pre-dose till at least 72 hours post-dose. Altogether, the subject will stay for consecutive 03 days and 04 nights in the facility.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OP2101

Treatment with Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)

Group Type EXPERIMENTAL

Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)

Intervention Type DRUG

Intervention:

The amount of study lotion (OP2101) used is 11 grams per subject, equivalent to 22 fingertip units (FTU). The lotion is applied to the subject on back and front of the trunk, both hands (palm and back) and both arms. An SOP for handling and application of the lotion ensures the 11 grams covers 54% of the body surface area (BSA) evenly without residue.

Comment:

The treatment is single-dose and single-treatment. The FTU is used to standardize the amount of cream being applied in clinical research. It is also used in clinical practice and hence connects the objectiveness of the trial to the clinical situation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)

Intervention:

The amount of study lotion (OP2101) used is 11 grams per subject, equivalent to 22 fingertip units (FTU). The lotion is applied to the subject on back and front of the trunk, both hands (palm and back) and both arms. An SOP for handling and application of the lotion ensures the 11 grams covers 54% of the body surface area (BSA) evenly without residue.

Comment:

The treatment is single-dose and single-treatment. The FTU is used to standardize the amount of cream being applied in clinical research. It is also used in clinical practice and hence connects the objectiveness of the trial to the clinical situation.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy male human subjects between 18 to 45 years of age (both inclusive).
2. Having a Body Mass Index (BMI) between 18.5 and 30.0 kg/m2 (both inclusive).
3. Have no abnormal findings during screening done 21 days prior to administration of study drug, medical history and examination, laboratory evaluations, 12-lead ECG recordings.
4. Has an optimum physical condition which enables subjects to be fit for a Pharmacokinetic sampling according to principal investigator's evaluation.
5. Able to comply with the study procedures in the opinion of the PI/CI.
6. Able to give written consent for participation in the study.
7. Subjects who have taken at least two doses of COVID 19 vaccine and possess certificate for the same.
8. Intact skin without major scarring or tattoos.
9. An unusual diet (e.g., low salt), for any medical reason or non-medical reason for three weeks prior to receiving the study drug and throughout the subjects' participation in the study. In any such case subject selection will be at the discretion of the PI/CI.

Exclusion Criteria

1. Known hypersensitivity or idiosyncratic reaction to Fexofenadine Hydrochloride or any of the excipients in the formulation.
2. Diagnosed with, or a family history of, long QT syndrome (LQTS).
3. Skin disorders or current skin discomforts.
4. Any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal, genital or any other body system.
5. Ingestion of any medicine at any time within 14 days before Check In. In any such case subject selection will be at the discretion of the PI/CI and medicine taken will be recorded.
6. Any history or presence of asthma (including aspirin induced asthma) or NSAID induced urticaria.
7. History of substance abuse and or addiction to drugs and alcohol.
8. Smokers, who smoke 9 or more cigarettes / day or inability to abstain during the study.
9. Habituated to drinking tea or coffee (more than 5 cups/day) or inability to abstain during the study
10. Habituated to tobacco/tobacco containing products (more than 10 gm/day) or inability to abstain during the study.
11. A positive result for Serological tests \[including hepatitis B \& C, HIV antibody and syphilis {VDRL (RPR) /TPHA}\] tests.
12. Donation of blood (1 unit: 350 mL) within 90 days prior to receiving the first dose of study drug.
13. The receipt of an investigational product or participation in a drug research study within a period of 90 days prior to the first dose of study drug.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes